The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections
Abstract
Objective.: The objective of this investigation was to establish the safety of high-dose (HD) acyclovir for the treatment of neonatal herpes simplex virus (HSV) disease. In addition, an estimate of therapeutic efficacy was sought, both with respect to mortality and to morbidity. Virologic efficacy of HD acyclovir was also assessed. Participants.: Infants who were ≤28 days old and whose disease was considered to be caused by HSV were enrolled in this study. Patients with central nervous system (CNS; N = 28) or disseminated (N = 41) HSV infection were offered participation in the trial. A small number of patients with HSV disease limited to the skin, eyes, or mouth (SEM; N = 10) or whose disease was clinically consistent with HSV but who did not have virologic confirmation of infection (N = 9) also were enrolled on a compassionate basis. Only patients with virologically confirmed HSV disease were included in efficacy analyses. All enrolled patients were included in safety analyses. Methods.: The study was an open-label evaluation of intravenous acyclovir at dosages higher than the 30 mg/kg/d standard dosage approved by the US Food and Drug Administration. The first 16 patients enrolled received intermediate-dose (ID) acyclovir (45 mg/kg/d), and the next 72 patients received HD acyclovir (60 mg/kg/d). Acyclovir was administered in 3 divided daily doses for 21 days. Neonates were assessed prospectively throughout treatment and at scheduled follow-up visits for the first 4 years of life. Data were compared with those of a previous National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group trial in which patients received standard-dose (SD) acyclovir for 10 days and in which identical methods (with the exception of acyclovir dosage and duration of therapy) were used. Results.: Six (21%) of 29 HD acyclovir recipients whose HSV disease remained localized to the SEM or CNS experienced neutropenia. One of the 6 had an absolute neutrophil count <500/mm3, and 5 patients had an absolute neutrophil count (ANC) between 500/mm3 and 1000/mm3. In all 6 cases, the ANC recovered during continuation of acyclovir at the same dosage or after completion of acyclovir therapy, and there were no apparent adverse sequelae of the transient neutropenia. No other drug-related adverse events were reported among ID or HD recipients, and no other laboratory aberrations could be correlated specifically with antiviral therapy. The survival rate for the patients with disseminated HSV disease treated with HD acyclovir was significantly higher than for those in the previous study treated with SD acyclovir, with an odds ratio (OR) of 3.3 (95% confidence interval [CI]: 1.4–7.9). For patients with CNS disease, however, survival rates were similar for the HD and SD groups. To assess the effect of HD acyclovir on survival for the entire population with neonatal HSV disease, the Cox proportional hazards regression analysis was performed with stratification for disease category (CNS versus disseminated). In performing this analysis, differences in mortality for each disease category were weighted to allow statistical comparison of the treatment dosage groups (HD, ID, and SD). This analysis indicated that the survival rate for patients treated with HD acyclovir was statistically significantly higher than for patients treated with SD acyclovir (OR: 3.3; 95% CI: 1.5–7.3). Recipients of HD acyclovir had a borderline significant decrease in morbidity compared with SD recipients, after stratification for the extent of disease (SEM vs CNS vs disseminated) and controlling for the potential confounding factors of HSV type (HSV-1 vs. HSV-2), prematurity, and disease severity (seizures). Patients treated with HD acyclovir were 6.6 times (adjusted OR; 95% CI: 0.8–113.6) as likely to be developmentally normal at 12 months of age as patients treated with SD therapy. Conclusion.: These data support the use of a 21-day course of HD (60 mg/kg/d) intravenous acyclovir to treat neonatal CNS and disseminated HSV disease. Throughout the course of HD acyclovir therapy, serial ANC determination should be made at least twice weekly. Decreasing the acyclovir dosage or administering granulocyte colony-stimulating factor should be considered if the ANC remains below 500/mm3 for a prolonged period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., Soong, S.-J., & The NIAID Collaborative Antiviral Study Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198601163140303 · Cited by 896
Self-citationNatural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era
Kimberlin, D. W., Lin, C.-Y., Jacobs, R. F., Powell, D. A., Frenkel, L. M., Gruber, W. C., Rathore, M., Bradley, J. S., Diaz, P. S., Kumar, M., et al. (2001) · Pediatrics · doi:10.1542/peds.108.2.223 · Cited by 507
Self-citationThe Natural History of Herpes Simplex Virus Infection of Mother and Newborn
Whitley, R. J., Nahmias, A. J., Visintine, A. M., Fleming, C. L., Alford, C. A., Yeager, A., Arvin, A., Haynes, R., Hilty, M., & Luby, J. (1980) · Pediatrics · doi:10.1542/peds.66.4.489 · Cited by 462
Self-citationPredictors of Morbidity and Mortality in Neonates with Herpes Simplex Virus Infections
Whitley, R., Arvin, A., Prober, C., Corey, L., Burchett, S., Plotkin, S., Starr, S., Jacobs, R., Powell, D., Nahmias, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240704 · Cited by 410
Self-citationA Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection
Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240703 · Cited by 388
Self-citationVidarabine Therapy of Neonatal Herpes Simplex Virus Infection
Whitley, R. J., Nahmias, A. J., Soong, S.-J., Galasso, G. G., Fleming, C. L., Alford, C. A., Connor, J., Bryson, Y., & Linnemann, C. (1980) · Pediatrics · doi:10.1542/peds.66.4.495 · Cited by 358
Self-citationKimberlin, D. W., Powell, D. A., Gruber, W. C., Diaz, P. S., Arvin, A. M., KUMAR, M. L., Jacobs, R. F., Dyke, R. V., Burchett, S. K., Soong, S., et al. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00014 · Cited by 155
Self-citationNeonatal Herpes Simplex Virus Infection: Follow-up Evaluation of Vidarabine Therapy
Whitley, R. J., Yeager, A. S., Kartus, P. L., Bryson, Y. J., Connor, J. D., Alford, C. A., Nahmias, A. J., & Soong, S. (1983) · PEDIATRICS · doi:10.1542/peds.72.6.778 · Cited by 136
Self-citationNeonatal acyclovir pharmacokinetics in patients with herpes virus infections
Hintz, M. A., Connor, J. D., Spector, S. A., et al. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90093-6 · Cited by 57
Use of acyclovir in premature and term neonates
Yeager, A. S. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90092-4 · Cited by 38
Cited by
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Herpes simplex virus infections
Whitley, R. J., & Roizman, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04638-9 · Cited by 1,366
Self-citationSimonsen, K. A., Anderson-Berry, A. L., Delair, S. F., & Davies, H. D. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-13 · Cited by 984
Whitley, R. J., & Roizman, B. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0597 · Cited by 700
Self-citationBrown, Z. A., Wald, A., Morrow, R. A., Selke, S., Zeh, J., & Corey, L. (2003) · JAMA · doi:10.1001/jama.289.2.203 · Cited by 679
Self-citation
Metadata
- Authors
- Kimberlin, D. W., Lin, C.-Y., Jacobs, R. F., Powell, D. A., Corey, L., Gruber, W. C., Rathore, M., Bradley, J. S., Diaz, P. S., Kumar, M., Arvin, A. M., Gutierrez, K., Shelton, M., Weiner, L. B., Sleasman, J. W., de Sierra, T. M., Weller, S., Soong, S.-J., Kiell, J., Lakeman, F. D., Whitley, R. J., & the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Groupa
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2001-08-01
- Volume
- 108
- Issue
- 2
- Pages
- 230-238
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2127472356
- Cited by
- 574
- References
- 11
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections. https://app.cochat.ai/papers/10.1542/peds.108.2.230
- The paper
- Kimberlin, D. W., Lin, C.-Y., Jacobs, R. F., Powell, D. A., Corey, L., Gruber, W. C., Rathore, M., Bradley, J. S., Diaz, P. S., Kumar, M., Arvin, A. M., Gutierrez, K., Shelton, M., Weiner, L. B., Sleasman, J. W., de Sierra, T. M., Weller, S., Soong, S.-J., Kiell, J., . . . the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Groupa. (2001). Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections. Pediatrics. https://doi.org/10.1542/peds.108.2.230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.